At the Forefront of Research

These tools are available to RMAPA patients through our affiliation with RMA of NJ.


Comprehensive Chromosomal Screening

When it comes to assisted reproductive technologies (IVF), the medical experts at RMA of NJ have pioneered and successfully implemented a cutting-edge technology, known as Comprehensive Chromosomal Screening (SelectCCS), to more accurately detect healthy embryos that will lead to successful pregnancies and ultimately healthy babies. Other centers have attempted similar testing methods, but RMANJ is the only fertility center in the world to have developed a system of unprecedented accuracy, fully validated through years of rigorous clinical research. RMANJ’s SelectCCS offers advanced embryo selection with extreme accuracy by detecting and avoiding use of embryos with chromosomal abnormalities prior to implantation and pregnancy. This advanced embryo selection technique will not only prevent specific conditions such as Down Syndrome, but also dramatically reduce miscarriage rates and reduce the need to implant multiple embryos to achieve conception. The ultimate reproductive medicine goal of “one embryo, one healthy baby” is now one large step closer to fruition.


Research at RMAPA

At RMAPA, research studies are always underway as we work to find innovative, safe and effective solutions for infertility.  Ongoing projects include randomized trials on the impact of biopsying embryos for PGD (pre-implantation genetic diagnosis) or SelectCCS (Comprehensive Chromosomal Screening) and the impact of egg freezing (oocyte vitrification).

If you are interested in any of the RMAPA studies or have questions, please call (610) 820-6888 or contact us online for an appointment to discuss with our physician the studies currently available.